{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.53","value":"-34.6"},{"groupId":"OG001","spread":"46.98","value":"-53.7"},{"groupId":"OG002","spread":"56.28","value":"-42.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.80","value":"-28.6"},{"groupId":"OG001","spread":"50.40","value":"-47.6"},{"groupId":"OG002","spread":"48.67","value":"-38.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.72","value":"-30.0"},{"groupId":"OG001","spread":"50.0","value":"-75.0"},{"groupId":"OG002","spread":"50.00","value":"-50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"Direct observation of ability to stand unaided: 0=able to stand easily with arms extended, 1=able to stand after several efforts without using arms as assistance, 2=able to stand only by using arms as assistance 3=completely unable to stand","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Muscle Strength","type":"SECONDARY","unitOfMeasure":"percent change in scores"}